Volume : 7, Issue : 8, August - 2018

STUDY OF VITAMIN B12 DEFICIENCY IN TYPE- 2 DIABETIC PATIENTS USING METFORMIN AT RIMS RAIPUR CHHATTISGARH

Dr. Sulekha Sharma, Dr Brajendra Kumar

Abstract :

<p style="background:white"><span style="font-size:11.0pt;color:black">The prevalence of vitamin B12 deficiency varies from 5.8% to 30% among patients undergoing long-term treatment with metformin.Our study aimed to determine the frequency of B12 deficiency and related factors among<span style="mso-spacerun:yes">&nbsp; </span>patients with type 2 diabetes mellitus (T2DM) using metformin.<a name="idm5497296"></a><a name="idm5496048"></a>Patients with T2DM and a control group of non-diabetics were included. Serum B12 levels were measured and biochemical B12 deficiency was defined as serum levels &lt; 180 pg/ml. Associations between B12 deficiency and age, duration of T2DM, duration of use and dosage of metformin, and use of proton pump inhibitors (PPIs) or histamine H2 antagonists were determined.<a name="idm5493792"></a>300 T2DM patients using metformin (T2DM-met) and 300 controls were included. No difference in the frequency of PPI or H2-antagonist use was seen between the groups. B12 deficiency was more frequent in the T2DM-met group (22.5%&nbsp;<em>versus</em>&nbsp;7.4%) and this difference persisted after excluding PPI/H2-antagonist users (17.9%&nbsp;<em>versus</em>&nbsp;5.6%). The factors that interfered with serum B12 levels were PPI/H2-antagonist use and duration of metformin use &ge; 10 years. Use of PPI/H2-antagonists was associated with B12 deficiency, with an odds ratio of 2.60 (95% confidence interval, 1.34-5.04).<a name="idm5491008"></a>Among T2DM patients, treatment with metformin and concomitant use of PPI/H2-antagonists are associated with a higher chance of developing B12 deficiency than among non-diabetics.<o:p></o:p></span></p>